Clinical Trial Update: Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial evaluates Ociperlimab (BGB-A1217) in combination with tislelizumab or rituximab for relapsed or refractory diffuse large B-cell lymphoma, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ociperlimab (ociperlimab)
• Rituximab (rituximab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-09-15